Since then, RET solvent front mutations have been reported in many other RET-altered NSCLC and MTC treated with either selpercatinib or pralsetinib, accounting for around 20–25% cases of acquired resistance (Lin et al. 2020, Subbiah et al. 2021a, Gainor et al. 2021b, Rosen et al. 2022, Hadoux et al. 2023b) (Fig. 3) (Supplementary Table). Here, RET is linked to non-small cell lung carcinoma.